Neuropace, Inc. Common Stock (NPCE)

Price$16.51

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)6.59%

Price vs S&P 500 (4W)-8.08%

VGM Score48.33

Market Capitalization$563.91M

All Metrics

Book Value / Share (Quarterly)$0.43

P/TBV (Annual)6.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)29.99%

Cash Flow / Share (Quarterly)$-0.29

Price vs S&P 500 (YTD)-3.81%

Gross Margin (TTM)78.29%

Net Profit Margin (TTM)-21.67%

EPS (TTM)$-0.65

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-0.65

Revenue Growth (5Y)19.44%

EPS (Annual)$-0.66

ROI (Annual)-27.55%

Gross Margin (Annual)77.23%

Net Profit Margin (5Y Avg)-57.82%

Cash / Share (Quarterly)$1.59

Revenue Growth QoQ (YoY)-2.02%

ROA (Last FY)-20.33%

Revenue Growth TTM (YoY)18.06%

EBITD / Share (TTM)$-0.51

ROE (5Y Avg)-159.09%

Operating Margin (TTM)-17.34%

Cash Flow / Share (Annual)$-0.34

P/B Ratio39.01x

P/B Ratio (Quarterly)30.63x

Net Income / Employee (Annual)$-102,700

EV / Revenue (TTM)6.11x

Net Interest Coverage (TTM)-3.83x

ROA (TTM)-20.64%

EPS Incl Extra (Annual)$-0.66

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)4.25x

3-Month Avg Trading Volume0.19M

52-Week Price Return26.16%

Revenue / Employee (TTM)$476,200

Tangible BV / Share (Quarterly)$0.62

P/S Ratio (Annual)5.64x

Asset Turnover (Annual)0.95x

52-Week High$19.60

Operating Margin (5Y Avg)-45.53%

EPS Excl Extra (Annual)$-0.66

CapEx CAGR (5Y)40.80%

26-Week Price Return22.52%

Quick Ratio (Annual)4.25x

13-Week Price Return10.12%

Total Debt / Equity (Annual)3.09x

Current Ratio (Quarterly)5.38x

Enterprise Value$608.15M

Revenue / Share Growth (5Y)11.44%

Asset Turnover (TTM)0.95x

Revenue / Employee (Annual)$478,400

Inventory Turnover (Annual)1.50x

Pretax Margin (Annual)-21.47%

Cash / Share (Annual)$1.82

3-Month Return Std Dev52.42%

Gross Margin (5Y Avg)74.03%

Net Income / Employee (TTM)$-103,200

ROE (Last FY)-112.79%

Net Interest Coverage (Annual)-3.97x

EPS Basic Excl Extra (Annual)$-0.66

Receivables Turnover (TTM)6.59x

Total Debt / Equity (Quarterly)4.08x

EPS Incl Extra (TTM)$-0.65

Receivables Turnover (Annual)7.26x

ROI (TTM)-28.12%

P/S Ratio (TTM)5.67x

Pretax Margin (5Y Avg)-57.82%

Revenue / Share (Annual)$3.06

Tangible BV / Share (Annual)$1.39

Price vs S&P 500 (52W)-2.04%

Year-to-Date Return7.12%

5-Day Price Return-2.25%

EPS Normalized (Annual)$-0.66

ROA (5Y Avg)-29.58%

Net Profit Margin (Annual)-21.47%

Month-to-Date Return-1.90%

Cash Flow / Share (TTM)$-1.49

EBITD / Share (Annual)$-0.51

Operating Margin (Annual)-16.84%

LT Debt / Equity (Annual)3.09x

ROI (5Y Avg)-38.63%

LT Debt / Equity (Quarterly)4.08x

EPS Basic Excl Extra (TTM)$-0.65

P/TBV (Quarterly)14.44x

P/B Ratio (Annual)27.02x

Inventory Turnover (TTM)1.43x

Pretax Margin (TTM)-21.67%

Book Value / Share (Annual)$0.57

Price vs S&P 500 (13W)0.37%

Beta1.91x

Revenue / Share (TTM)$2.95

ROE (TTM)-120.74%

52-Week Low$7.56

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.20est. -0.23

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
NPCENeuropace, Inc. Common Stock	D	C	B	$16.51
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

NeuroPace develops implantable neuromodulation systems to treat epilepsy through its RNS System, which continuously monitors brain electrical activity and delivers personalized seizure prevention therapy. The company's comprehensive platform integrates implantable devices, clinical monitoring software, and patient management tools that support ongoing treatment outcomes. NeuroPace generates revenue from device sales, implantation procedures, and subscription-based patient management services.